Sanofi-aventis U.S.

Paul Chew, M.D., has been appointed to Chief Science Officer/Chief Medical Officer, for sanofi-aventis, U.S., effective April 1. He was previously President, R&D, sanofi-aventis, U.S.

In these roles, Dr. Chew will establish a unified medical voice for sanofi-aventis U.S. among internal and external stakeholders. He will be responsible for overseeing U.S. medical affairs in addition to his continued oversight of the U.S. R&D organization in coordination with the parent company in Paris. Further, Dr. Chew will be charged with representing accurate and timely clinical and safety information to health authorities, payers, patients and physicians that will foster safe and appropriate use of our products.

Dr. Chew will report primarily to Greg Irace, president and chief executive officer, sanofi-aventis U.S., in addition to Marc Cluzel, group senior vice president of R&D and Jean-Pierre Lehner, group chief medical officer.

“Paul brings deep scientific expertise and proven leadership to both the R&D and Medical functions in the U.S. — a critical area in which the science and the business of our industry intersect,” said Greg Irace. “In this new role, Paul will be in a position to bring greater scientific and product insights to our organization, greater clarity and dialogue with members of the healthcare system and, ultimately, greater value to patients in the form of improved health outcomes.”

The new roles are part of the company’s overall organizational drive to ensure all components of the U.S. affiliate work in a coordinated manner to achieve harmonized processes, cost-effectiveness and best practice sharing in the design, conduct and monitoring of clinical studies.